药物警戒新时代:走向真实世界数据与数字化监测
药物不良反应(ADR)对患者、临床医生和监管机构构成重大关切。本文概述了现代药物警戒的多种路径,包括自发报告数据库、电子健康记录监测与研究框架、社交媒体监测及数字设备应用,并指出部分平台已成熟而另一些仍在兴起或实验阶段,强调需进一步研究与投资互补性药物警戒系统以保障药物治疗安全。
要点
- 现代药物警戒已拓展至真实世界数据与数字化监测等多条路径。
- 自发报告数据库、电子健康记录、社交媒体和数字设备各有成熟度差异。
- 需持续研究与投资互补性药物警戒系统以保障用药安全。
核心结论
- 现代药物警戒正走向真实世界数据与数字化监测,多种平台已开始影响药物研发与上市后安全监测格局。
研究设计与样本
- 本文为综述,概述了自发报告数据库、电子健康记录监测与研究框架、社交媒体监测及数字设备等药物警戒路径。
主要发现
- 部分药物警戒平台已成熟,另一些仍处于兴起或实验阶段。
- 这些药物警戒系统已开始影响药物开发过程及上市后药物安全监测格局。
临床怎么用
- 临床药学智能体可关注真实世界数据与数字化监测平台作为传统自发报告的补充。
- 在解读药物安全信号时需考虑不同药物警戒平台的成熟度与局限性。
局限性
- 部分药物警戒平台仍处于兴起或实验阶段,现有系统存在挑战。
- 需进一步研究与投资互补性药物警戒系统以确保药物治疗持续安全。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Adverse drug reactions (ADRs) are a major concern for patients, clinicians, and regulatory agencies. The discovery of serious ADRs leading to substantial morbidity and mortality has resulted in mandatory phase IV clinical trials, black box warnings, and withdrawal of drugs from the market. Real-world data, data collected during routine clinical care, is being adopted by innovators, regulators, payors, and providers to inform decision making throughout the product life cycle. We outline several different approaches to modern pharmacovigilance, including spontaneous reporting databases, electronic health record monitoring and research frameworks, social media surveillance, and the use of digital devices. Some of these platforms are well-established while others are still emerging or experimental. We highlight both the potential opportunity, as well as the existing challenges within these pharmacovigilance systems that have already begun to impact the drug development process, as well as the landscape of postmarket drug safety monitoring. Further research and investment into different and complementary pharmacovigilance systems is needed to ensure the continued safety of pharmacotherapy.
引用
- Lavertu A, Vora B, Giacomini KM, et al. A New Era in Pharmacovigilance: Toward Real-World Data and Digital Monitoring. Clin Pharmacol Ther. 2021. PMID: 33492663. doi:10.1002/cpt.2172
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。